Cochrane · systematic review · CD011547
Artemisinin‐naphthoquine for treating uncomplicated Plasmodium falciparum malaria
Isba, R, Zani, B, Gathu, M, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
Infectious DiseasesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 3 · 75%Low 1 · 25%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Artemisinin‐naphthoquine versus AL for treating uncomplicated P. falciparum malaria
Population: Adults and children with uncomplicated P. falciparum malaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment failure at day 28 Artemisinin‐naphthoquine vs AL | RR 1.02 [0.24, 4.37] | 3 studies · 487 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Treatment failure at day 42 Artemisinin‐naphthoquine vs AL | RR 0.09 [0, 1.59] | 1 study · 186 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Artemisinin‐naphthoquine versus DHA‐P for treating uncomplicated P. falciparum malaria
Population: Adults and children with uncomplicated P. falciparum malaria
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment failure at day 28 Artemisinin‐naphthoquine vs DHA‐P | no estimate extracted | 1 study · 143 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Treatment failure at day 42 Artemisinin‐naphthoquine vs DHA‐P | RR 0.91 [0.13, 6.26] | 1 study · 143 participants | Very low Downgraded: risk of bias, imprecision, indirectness |